A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Phase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in
patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies,
to determine the DLT and MTD, or MAD, and to determine RP2D. Phase II Main objective: To
explore the efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and
other hematological malignancies.